Perspective from Jay Giri, MD, MPH, FAHA
October 25, 2019
2 min read

IVUS-XPL: In long lesions, IVUS-guided PCI retains superior outcomes at 5 years

Perspective from Jay Giri, MD, MPH, FAHA
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Myeong-Ki Hong

SAN FRANCISCO — Among patients who underwent PCI for long lesions, IVUS-based guidance was associated with better outcomes than angiography-based guidance at 5 years, according to new data from the IVUS-XPL trial presented at TCT 2019.

As Healio previously reported, at 1 year, among patients who had PCI with an everolimus-eluting stent (Xience Prime, Abbott Vascular), those who had IVUS guidance had reduced risk for MACE (HR = 0.48; 95% CI, 0.28-0.83).

In the 5-year results, presented here by Myeong-Ki Hong, MD, PhD, professor of medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine in Seoul, South Korea, and published in JACC: Cardiovascular Interventions, MACE remained lower in the IVUS group compared with the angiography group (5.6% vs. 10.7%; HR = 0.5; 95% CI, 0.34-0.75). MACE was defined as cardiac death, target lesion-related MI or ischemia-driven target lesion revascularization.

As with the 1-year results, the 5-year results were mainly driven by differences in ischemia-driven TLR (4.8% vs. 8.4%; HR = 0.54; 95% CI, 0.33-0.89), Hong said during a presentation.

When the researchers performed a landmark analysis, they determined that between 1 year and 5 years, the rates of MACE were 2.8% in the IVUS group and 5.2% in the angiography group (HR = 0.53; 95% CI, 0.29-0.95).

Other 5-year analyses showed the treatment effect was similar across all subgroups.

“Sustained 5-year clinical benefits resulted from both within 1 year and from 1 to 5 years postimplantation, even in the current DES implantation era,” Hong said during the presentation.

The cohort included 1,400 patients (mean age, 64 years; 69% men; minimum estimated stent length, 28 mm), of whom 589 from the IVUS group and 594 from the angiography group completed 5-year follow-up. – by Erik Swain


Hong M-K, et al. Late-Breaking Science 4. Presented at: TCT Scientific Symposium; Sept. 25-29, 2019; San Francisco.

Hong S-J, et al. JACC Cardiovasc Interv. 2019;doi:10.1016/j.jcin.2019.09.033.

Disclosures: Hong reports no relevant financial disclosures. Another author reports he consults for Boston Scientific, Philips/Volcano and Terumo.